Researchers Assess Breast Cancer Risk Assessment Models
A study published in the latest issue of the Journal of the National Cancer Institute analyzed the performance of breast cancer risk assessment models.
“Few...
FDA Approves New Treatment for Aggressive Breast Cancer
The U.S. Food and Drug Administration approved Trodelvy™ (sacituzumab govitecan-hziy) for patients with metastatic triple-negative breast cancer who have received at least two prior...
Is Utilization Management Policy Correlated with Uptake of Hypofractionated Radiotherapy in Early-Stage Breast Cancer?
A study evaluated the relationship between utilization management policy and uptake of hypofractionated radiotherapy in patients with early-stage breast cancer.
“Breast cancer accounts for the...
FDA Approves Breast Cancer Treatment Through International Approval Pathway
The U.S. Food and Drug Administration (FDA) approved Tukysa™ (tucatinib) in combination with trastuzumab and capecitabine for the treatment of advanced human epidermal growth...
App Successfully Detects Lymphedema in Breast Cancer Patients
An estimated 20% of breast cancer patients develop lymphedema, which causes swelling of the arms. Researchers recently assessed the value of an app to...
Do Breast Cancer Treatment Outcomes Vary Based on Germline Variant Status?
A new study evaluated the effectiveness of breast cancer treatment based on germline variant status.
“The GeparOcto randomized clinical trial compared the efficacy of 2...
Breast Cancer Survivors Suffer ‘Greater Loss of Well-Being’ than Noncancer Patients Later in Life
For breast cancer patients, the adverse effects of the cancer and its treatments do not cease when the disease leaves the body, and well-being...
